Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Diabetes
•
Endocrinology
•
Obesity Medicine
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
Related Questions
Do you recommend the use of GLP1 R agonist therapy in patients with T1DM for weight loss?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
How do you counsel patients on the use of compounded weight loss medications?
Is there a role for use of GLP1 R agonist or dual agonist therapy for management of post bariatric hypoglycemia and dumping syndrome?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
Should we be using body fat percentage instead of BMI for determining patients' risk of metabolic syndrome?
Do you use the homeostatic model assessment (HOMA) to assess for insulin resistance and change your clinical management of patients?
Should we recommend SGLT2i initiation at discharge to all patients hospitalized with acute myocardial infarction?
Do you recommend non-bypass bariatric surgeries over intestinal bypass procedures for kidney transplant-eligible candidates to prevent oxalate nephropathy, given the higher risk of kidney oxalate deposition with intestinal bypass?
Would you recommend statin initiation in a young adult patient (age < 40) with type 1 diabetes mellitus and LDL cholesterol levels greater than 100 without any cardiovascular risk factors?
